Evaluation of different screening methods to understand the dissolution behaviors of amorphous solid dispersions

Drug Development and Industrial Pharmacy

Volumn 40, Issue 8, 2014, Pages 1072-1083

  Lee, Thomas Wai Yip ^a   Boersen, Nathan A ^a   Yang, Gang ^a   Hui, Ho Wah ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Polymers; Poorly soluble compounds; Precipitation; Recrystallization; Supersaturation

Indexed keywords

EUDRAGIT; METHYLCELLULOSE; POVIDONE DERIVATIVE; CELLULOSE; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; MICROCAPSULE; POLYMER; POLYMETHACRYLIC ACID DERIVATIVE; POVIDONE; POWDER;

AMORPHOUS SOLID DISPERSION; ARTICLE; COMPLEX FORMATION; CONTACT ANGLE; CRYSTALLIZATION; DISSOLUTION; DRUG CAPSULE; DRUG DOSAGE FORM; MELTING POINT; MISCIBILITY; PHASE SEPARATION; POWDER; PRECIPITATION; QUANTITATIVE ANALYSIS; SCREENING; SEDIMENTATION; STOMACH JUICE; TABLET; TABLET HARDNESS; VELOCITY; CHEMISTRY; HEAT; MEDICINAL CHEMISTRY; MICROCAPSULE; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

CAPSULES; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; HOT TEMPERATURE; POLYMERS; POLYMETHACRYLIC ACIDS; POVIDONE; POWDERS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84905456922     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.807279     Document Type: Article

References (30)

1. Lee TW, Boersen N, Hui H-W, Kurtulik P. Oral Delivery of Poorly Soluble Compounds by Supersaturated Systems. Ther Deliv 2011;6: 285-90.
2. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86: 1-12.
3. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev 2001;48:27-42.
4. Crowley KJ, Zografi G. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state. Pharm Res 2003;20: 1417-22.
5. Cai T, Zhu L, Yu L. Crystallization of organic glasses: effects of polymer additives on bulk and surface crystal growth in amorphous nifedipine. Pharm Res 2011;28:2458-66.
6. Shah N, Iyer RM, Mair HJ, et al. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci 2013;102:967-81.
7. Qian F, Wang J, Hartley R, et al. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Pharm Res 2012;29:2765-76.
8. Alonzo DE, Zhang GG, Zhou D, et al. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 2010;27:608-18.
9. Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res 2008;25:969-78.
10. Andronis V, Zografi G. The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm Res 1998;15:835-42.
11. Andronis V, Zografi G. Molecular mobility of supercooled amorphous indomethacin, determined by dynamic mechanical analysis. Pharm res 1997;14:410-14.
12. Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 1995;12:799-806.
13. Tong P, Zografi G. A study of amorphous molecular dispersions of indomethacin and its sodium salt. J Pharm Sci 2001;90:1991-2004.
14. Tong P, Zografi G. Solid-state characteristics of amorphous sodium indomethacin relative to its free acid. Pharm Res 1999;16:1186-92.
15. Hancock BC, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res 1994;11:471-7.
16. Strydom S, Liebenberg W, Yu L, de Villiers M. The effect of temperature and moisture on the amorphous-to-crystalline transformation of stavudine. Int J Pharm 2009;379:72-81.
17. Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2008;70:493-9.
18. Alonzo DE, Gao Y, Zhou D, et al. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci 2011;100: 3316-31.
19. Six K, Leuner C, Dressman J, et al. Thermal properties of hot-stage extrudates of itraconazole and Eudragit E100: phase separation and polymorphism. J Therm Anal Calori 2002;68:591-601.
20. Lakshman JP, Cao Y, Kowalski J, Serajuddin AT. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly watersoluble drug. Mol Pharm 2008;5:994-1002.
21. Newman A, Engers D, Bates S, et al. Characterization of amorphous API:Polymer mixtures using X-ray powder diffraction. J Pharm Sci 2008;97:4840-56.
22. Puri V, Dantuluri AK, Bansal AK. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion. J Pharm Sci 2011;100:2460-8.
23. Lee TW, Boersen N, Chen M, et al., editors. Overcoming plug formation in an amorphous solid dispersion during dissolution. American Association of Pharmaceutical Scientists Annual Meeting; 2011; Washington, D.C.
24. Qian F, Wang J, Hartley R, et al. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Pharm Res 2012;29:2765-76.
25. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 2010;99:1254-64.
26. Hancock B, Colvin J, Mullarney M, Zinchuk A. The relative density of pharmaceutical powders, blends, dry granulations and immediate release tablets. Pharm Technol 2003;27:64-80.
27. Parrott E, Wurster D, Higuchi T. Investigation of drug release from solids. I. Some factors influencing the dissolution rate. J Am Pharm Assoc 1955;44:269-73.
28. Huber H, Christenson G. Utilisation of hydrophilic gums for the control of drug substance release from tablet formulations II. Influence of tablet hardness and density on dissolution behavior. J Pharm Sci 1968;57:164-6.
29. Phuapradit W, Bolton S. The influence of tablet density on the human oral absorption of sustained release acetaminophen matrix tablets. Drug Dev Ind Pharm 1991;17:1097-107.
30. Pesonen T, Paronen P, Ilkka J. Dissolution properties of direct compression tablets containing an agglomerated cellulose powder. Drug Dev Ind Pharm 1992;18:159-73.